Transaction · 0001520262-26-000118

Hopkinson Craig C.

Hopkinson Craig C., ER, D, CMO, reported an open-market or private sale at Alkermes plc. involving 9000.000000 shares for an estimated $422874.00. Reported holdings after the transaction were 65389.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SER, D, CMO
ALKSAlkermes plc.
Filing timeSep 01
Trade dateSep 01, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$47.20
Pre-filing
1mo ago +3.8%1w ago +4.3%1d ago -0.4%
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

ALKS price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ALKS since 2026-09-01Filed 2 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001520262-26-000118
Ordinary Shares
Transaction date
Sep 01, 2026
Filed Sep 01, 2026, 11:08 PM · 0d delay
Shares
9.00k sh
$4.69k per share
Estimated value
-$42.2M
Computed from shares × price
Holdings after
65.3k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

EVP R&D, Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

  2. F2

    This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

  3. F3

    The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.8269 to $47.3197. Full information regarding the number of shares s…

  4. F4

    These options are fully vested in accordance with their terms.

Original filing · 0001520262-26-000118
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ALKS